Sun Pharma SAHPRA nod sets up generic semaglutide launch

What SAHPRA approved and why it matters

Sun Pharmaceutical Industries said it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa. The approval is for treating adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. Sun Pharma said it plans to launch the product in the market in the coming days. With this clearance, South Africa becomes the second market after India where the company has received approval for generic semaglutide. The development matters because semaglutide is part of the GLP-1 receptor agonists class, which has drawn strong demand in diabetes and, in select cases, weight management, depending on approvals.

Launch plans: “in the coming days”

Sun Pharma’s statement indicates that the South Africa launch is intended to follow quickly after the regulatory clearance. While the company did not share pricing, device details, or specific launch date for South Africa in the provided information, it framed the rollout as imminent. A near-term launch signals the company’s intent to move rapidly once approvals are secured, similar to its approach in India around the patent expiry window. The move also highlights how Indian generic manufacturers are targeting multiple geographies for the same molecule as regulatory pathways open.

South Africa is the second approval market after India

Sun Pharma’s South Africa approval comes after a series of regulatory and commercial milestones in India. In January 2026, the company received DCGI approval to manufacture and market generic semaglutide injection in India. It had planned to launch the product under the brand name Noveltreat after the expiry of the semaglutide patent in India. The company later launched semaglutide injection in India in March 2026 under the brand names Noveltreat and Sematrinity. The South Africa decision extends the company’s footprint for semaglutide beyond its home market.

India’s patent expiry triggered a rush of Day-1 generic launches

In India, semaglutide lost patent protection on the active ingredient, following which multiple domestic players rolled out generic versions on March 21. Companies cited as launching include Sun Pharma, Dr Reddy’s Laboratories, Zydus Life Sciences, Glenmark Pharmaceuticals, Alkem Laboratories, and Natco Pharma. The pricing strategy was positioned as central to the launch playbook because innovator products in this category were priced significantly higher. The launches also underscore how quickly the Indian branded generics market can respond once patent barriers fall.

How Sun Pharma positioned Noveltreat and Sematrinity in India

Sun Pharma launched two brands in India: Noveltreat for chronic weight management and Sematrinity for type 2 diabetes. Noveltreat was made available in five dose strengths, and the weekly therapy costs were stated to range from approximately ₹900 to ₹2,000, translating to roughly ₹3,600 to ₹8,000 per month. Sematrinity was described as coming in two dose strengths priced between ₹750 and ₹1,300 per week. The products were also described as pre-filled pen devices manufactured in Europe. Sun Pharma said the products were priced significantly lower than the innovator brand.

Price points in India: generics versus the innovator

One data point cited for Sun’s India pricing is ₹750 per injection, which totals approximately ₹3,400 per month. In contrast, Novo’s retail price in India was cited in a range of ₹8,800 to ₹10,000 depending on dosage, and another reference put starting-dose monthly pricing at ₹8,800 and ₹10,850 for its brands. The article also notes that Sun Pharma and Dr Reddy’s priced semaglutide about 50% lower than Novo’s initial prices. It further adds that smaller domestic-focused companies such as Natco Pharma and Alkem Laboratories offered steeper discounts of nearly 80%.

Competitive landscape: Dr Reddy’s, Zydus, Glenmark and others

Dr Reddy’s was described as the first Indian pharma company to receive DCGI approval for generic semaglutide and launched its brand Obeda. Obeda was priced at ₹4,200 per month for 2 mg and 4 mg doses, and was approved for type 2 diabetes management. The cluster of launches by several companies reflects a competitive market structure where multiple branded formulations can coexist. It also reinforces that approvals and indications differ by product, with some brands marketed for diabetes management and others for chronic weight management.

Market impact and opportunity sizing from Systematix

Systematix Institutional Equities estimated that semaglutide patent expiry could create an incremental revenue opportunity of over ₹50,000 million over the next 12-15 months across India, Brazil, and Canada. For India alone, it estimated an additional ₹10,000 to ₹20,000 million in revenue for the branded formulations market in FY27. The opportunity was expected to be shared among 10-15 Indian and global generic players, with names mentioned including Sun Pharma, Dr Reddy’s, Eris Lifesciences, Cipla, Lupin, Alkem, Zydus Lifesciences, and Biocon. These figures frame why multiple companies are prioritising quick launches and aggressive pricing.

Stock move and recent trading levels

Sun Pharma shares rose 2% to ₹1,841.90 in Wednesday’s intra-day trade on the BSE, extending gains for a fifth straight trading day. The stock was up 5% over the last one week, according to the provided data. It was quoted close to its 52-week high of ₹1,850.95, which was touched on May 2, 2025. The stock was also stated to have bounced back 16% from a three-month low of ₹1,583.60 hit on January 29, 2026. Another snapshot in the data showed the stock closing at ₹1,763.3, up 1.82% from the previous close of ₹1,731.8, with intraday high of ₹1,770.4 and low of ₹1,733.4, and volume of 1,200,996 shares.

Financial context: Q3 FY26 growth and R&D intensity

Sun Pharma’s Q3 FY26 revenue grew 11% year-on-year to ₹143,458 million, supported by global specialty businesses, including the US and other markets, and domestic formulations. Adjusted net profit increased 12%, and the company invested 6.4% of sales in R&D, as per the provided information. The company also highlighted regulatory approvals for semaglutide generics across weight management and type 2 diabetes in India. These operational metrics provide context for why regulatory milestones can attract investor attention, especially when paired with large market opportunities in metabolic therapies.

Key facts table

Conclusion

Sun Pharma’s SAHPRA approval positions it to bring a generic semaglutide injection to South Africa shortly, marking its second approval market for the molecule after India. The company’s India experience shows how pricing and swift execution matter when multiple generics launch soon after patent barriers lift. Investors are also watching these developments alongside the company’s Q3 FY26 revenue growth to ₹143,458 million and continued R&D spending at 6.4% of sales. The next concrete step, based on Sun Pharma’s statement, is the South Africa product launch in the coming days.